CENTOGENE is the unique and essential partner for patients, physicians, and biopharma in rare, metabolic, and neurodegenerative diseases, covering diagnostics, discovery, clinical development, and market access. With a global reach spanning over 100 countries and a network of 30,000 physicians, we've diagnosed over 2,500 rare diseases. Our extensive testing portfolio of 19,000+ genes and 10,000+ tests, revolutionizes early disease detection. We engaged with MCS for Penetration testing for our publicly available endpoints. After considering various factors, including reputation, reliability, cost-effectiveness, and alignment with our organizational goals, among well-recognized candidates, it was agreed that MCS best met our requirements. Our project with MCS went smoothly; their structured approach and timely delivery were commendable. Our experience was positive and contributed to improving our security measures; we would definetely recommend them.
CENTOGENE
CENTOGENE - The Rare Disease Company